Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PHRRF$0.04+0.00(+2.70%)PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157[10:01:00 AM ET]SMX$1.82+0.04(+2.25%)TechCrunch Feature on SMX Latest in Media Coverage of Company's Growing Global Profile and Technology[10:00:00 AM ET]ROK$447.08+3.26(+0.74%)Rockwell Automation Introduces SecureOT Capabilities to Help OEMs Address Emerging Cybersecurity Regulations Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation, today announced new ...[10:00:00 AM ET]APPN$50.86-1.10(-2.12%)Appian Announces 2026 US Public Sector Partner Award Winners Appian (Nasdaq: APPN) today announced the winners of its 2026 US Public Sector Partner Awards at Appian Government. The annual awards recognize...[10:00:00 AM ET]EDGM$0.00-0.00(-33.33%)EdgeMode Answers the Call for Ready-to-Build Data Center Infrastructure to Shorten Lead Times[10:00:00 AM ET]AUXXF$0.30+0.02(+6.05%)A2GOLD TO SELL BOLO FOR $1.5 MILLION AND UP TO $2.8M IN CONTINGENT PAYMENTS A2Gold Corp. ("A2Gold" or the "Company") (TSX-V: AUAU) (OTCQX: AUXXF) (FRA: RR7) is pleased to announce that it has entered into a definitive Mining...[9:41:00 AM ET]ZENA$0.92-0.00(-0.40%)AI Transforming Land Surveying as Billions in Geospatial and Construction Markets Fuel New Growth Opportunities[9:40:00 AM ET]SGU$13.06-0.02(-0.11%)Bally's Corporation Comments on The Star Entertainment Group AUSTRAC Decision and Continued Turnaround[9:39:00 AM ET]AIDX$0.25-0.00(-1.17%)20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy[9:37:50 AM ET]NVAX$10.40+0.08(+0.78%)Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19...[9:37:00 AM ET]APPN$50.86-1.10(-2.12%)Appian Marks Major Milestone in Supporting US Army Ammunition Modernization Appian (NASDAQ: APPN) today announced that the US Army fielded the initial release of the Total Army Combat and Training Munitions Information System ...[9:35:00 AM ET]DTE$133.35+1.38(+1.05%)DTE Energy and sonnen Launch Michigan's First Residential Battery Virtual Power Plant Pilot to Explore New Ways to Lower Energy Costs DTE Energy and sonnen today announced the launch of Michigan's first residential battery virtual power plant (VPP) pilot at Veridian at County Farm,...[9:34:00 AM ET]MAN$45.39-0.36(-0.79%)TAPFIN Marks Five Consecutive Years of Everest Group SOW PEAK Matrix® Leadership Talent Solutions TAPFIN, part of the ManpowerGroup (NYSE: MAN) family of brands, has been named a Global Leader and Star Performer in the Everest...[9:31:00 AM ET]

IMCR · NASDAQ

Immunocore Holdings plc

$32.09 -0.58 (-1.78%)

Company overview

Immunocore Holdings plc, a commercial-stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other oncology programs include IMC-C103C, which is in a Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers, and IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.7B
Employees
493
Headquarters
Abingdon
Website
immunocore.com
CEO
Bahija Jallal
Listed
February 5, 2021
P/E
-86.19
Dividend yield
0.00%

Company financials

Revenue
$386M
Gross profit
$381M
Operating income
-$29.4M
EBITDA
-$2.1M
Net income
-$18.8M
EPS
-$0.37
Total assets
$1.1B
Total debt
$42M
Gross margin
98.81%
Net margin
-4.88%
Earnings yield
-1.16%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

27.0829.9032.7335.5538.37
IMCR 1D NASDAQ O31.61H32.72L30.01C32.67+0.71 (+2.22%)Vol68.27K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
IMCRImmunocore Holdings plc Press release Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting GlobeNewswire
IMCRImmunocore Holdings plc Press release Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes GlobeNewswire
IMCRImmunocore Holdings plc Stock news Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study Zacks Investment Research
IMCRImmunocore Holdings plc Stock news Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
IMCRImmunocore Holdings plc Press release Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma GlobeNewsWire
IMCRImmunocore Holdings plc Press release Immunocore to present at upcoming investor conferences GlobeNewswire
IMCRImmunocore Holdings plc Stock news Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026? Zacks Investment Research
IMCRImmunocore Holdings plc Stock news IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum Zacks Investment Research
IMCRImmunocore Holdings plc Stock news Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation? Zacks Investment Research
IMCRImmunocore Holdings plc Stock news IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss Zacks Investment Research
IMCRImmunocore Holdings plc Stock news Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues Zacks Investment Research
IMCRImmunocore Holdings plc Stock news Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? Zacks Investment Research
IMCRImmunocore Holdings plc Stock news Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript Seeking Alpha
IMCRImmunocore Holdings plc Stock news Immunocore Q2 Earnings Call Highlights MarketBeat
IMCRImmunocore Holdings plc Stock news Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead Zacks Investment Research
IMCRImmunocore Holdings plc Stock news Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth? Zacks Investment Research
IMCRImmunocore Holdings plc Stock news How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak Zacks Investment Research
IMCRImmunocore Holdings plc Stock news 4 Biotech Stocks Investors Should Watch in 2026 Zacks Investment Research
IMCRImmunocore Holdings plc Stock news Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Globe News Wire
IMCRImmunocore Holdings plc Press release Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma GlobeNewsWire
See more
FAQ

Questions about Immunocore Holdings plc

What does Immunocore Holdings plc do?
Immunocore Holdings plc, a commercial-stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other oncology programs include IMC-C103C, which is in a Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers, and IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.
What is IMCR's market cap?
Immunocore Holdings plc (IMCR) is a listed stock with a live quote. The latest market cap on this page is $1.7B.
Where is Immunocore Holdings plc headquartered?
Immunocore Holdings plc is headquartered in Abingdon.
How do I get IMCR news from the API?
Call GET /v1/news?tickers=IMCR. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does IMCR news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IMCR, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the IMCR price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs